The problem is not that we lack patent unencumbered medicine, the problem is that only patent encumbered medicine has the incentives behind it to fund studies i

The problem is not that we lack patent unencumbered medicine, the problem is that only patent encumbered medicine has the incentives behind it to fund studies into its safety, and the rest of the FDA process.